IMMUNOLOGY2026™ Conference Recordings For Attendees-Cancer-associated metabolites stimulate mucosal-associated invariant T cells for cancer cell killing.

Cancer-associated metabolites stimulate mucosal-associated invariant T cells for cancer cell killing.

Video Transcription

Video Summary

Ariel, a PhD student, presented research on a potential new glioblastoma treatment using MAIT cells, an unconventional T cell type that recognizes metabolite antigens through the conserved MR1 protein. The study found that glioblastoma cells can present an MR1-restricted metabolite signal that activates MAIT cells, which then kill tumor cells. Methylglyoxal enhanced this activation, and mass spectrometry identified a guanosine derivative as the likely cancer-associated ligand. Blocking MR1 prevented MAIT activation and tumor killing. The work suggests this metabolite-driven immune mechanism may offer a broader, more generalizable cancer immunotherapy strategy.

Meta Tag

Date April 17, 2026 4:30 PM - 4:45 PM

Room 153AB

Session Cellular Responses and the Tumor Microenvironment

Speaker Ariel Laub

Track Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

Year 2026

Keywords

glioblastoma

MAIT cells

MR1

methylglyoxal

cancer immunotherapy

April 17, 2026 4:30 PM - 4:45 PM

153AB

Cellular Responses and the Tumor Microenvironment

Ariel Laub

Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

2026